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Abstract
According to current diagnostic criteria, polycystic ovary syndrome (PCOS) is effective as a diagnosis of exclusion. Here, we present 
a case of a 31-year-old woman with a history of oligomenorrhoea and hirsutism, who, despite a “muscular” appearance and a normal 
body mass index (22.27 kg/m2), was found to have an extreme insulin resistance and diabetes accompanied by hyperandrogenism and 
polycystic ovaries. An autoimmune screen for possible latent autoimmune diabetes in adults was negative. She was subsequently found 
to have familial partial lipodystrophy (FPLD2, OMIM #151660) caused by an R482Q mutation in the LMNA gene encoding lamin A/C. 
This mutation results in arginine to glutamine substitution at the protein level, while phenotypically this condition presents with a loss 
of body fat, insulin resistance, dyslipidaemia, and other features mimicking PCOS. Interestingly her mother, with a history of myocardial 
infarction and diabetes at the age of 46 but no oligomenorrhoea, was also found to harbour the same mutation (LMNA R482Q). 
Conclusions: Our case highlights the importance of assessment of adipose tissue distribution, as well as a significance of assessment of 
glucose tolerance and insulin resistance in the differential diagnosis of PCOS. Furthermore, patients with atypical adipose tissue distribu-
tion should be referred for formal genetic testing. (Endokrynol Pol 2015; 66 (6): 550–554)
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Streszczenie
Według aktualnych kryteriów diagnostycznych, zespół policystycznych jajników (PCOS) jest rozpoznaniem z wykluczenia. W pracy przed-
stawiono przypadek 31-letniej kobiety z wywiadem zaburzeń miesiączkowania o typie rzadkich miesiączek oraz hirsutyzmu, u której mimo 
„muskularnego” wyglądu i prawidłowego wskaźnika masy ciała (22,27 kg/m2) stwierdzono bardzo wysoką insulinooporność, cukrzycę 
i hiperandrogenizm ze współistniejącą morfologią policystycystyczną jajników. Badania autoimmunologiczne w kierunku możliwej autoim-
munologicznej cukrzycy u dorosłych (tzw. LADA) były ujemne. Przeprowadzono diagnostykę genetyczną, rozpoznając rodzinną lipodystrofię 
częściową spowodowaną przez mutację laminy A/C genu R842Q (FPLD2, OMIM # 151660). Powyższa mutacja prowadzi do podstawienia 
argininy glutaminą (R482Q) na poziomie białka, natomiast fenotypowo objawia się utratą tkanki tłuszczowej, insulinoopornością, dyslipidemią, 
jak również cechami naśladującymi PCOS. Co ciekawe u matki pacjentki również rozpoznano tę samą mutację (lamina A/C genu R842Q). 
U matki wystąpił również zawał serca i cukrzyca w wieku 46 lat, jednak nie było u niej zaburzeń miesiączkowania o typie oligomenorrhoea.
Wnioski: Opisany przypadek podkreśla znaczenie oceny dystrybucji tkanki tłuszczowej, jak również znaczenie oceny tolerancji glukozy 
i insulinooporności w diagnostyce różnicowej PCOS. Autorzy pracy zalecają również, aby pacjentki z nietypowym rozkładem tkanki 
tłuszczowej były kierowane do dalszej diagnostyki genetycznej. (Endokrynol Pol 2015; 66 (6): 550–554)
Słowa kluczowe: insuliooporność; lipodystrofia; zespół policystycznych jajników
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Presentation
A 31-year-old female (IZ-821203) presented with a his-
tory of oligomenorrhoea and excessive hair growth. Her 
menstrual cycles were irregular since menarche (age 12). 
She finally decided to investigate her irregular periods as 
she was planning to get married. She was a non-smoker, 
did not take any regular medication, and was working as 
a clerk in a regional court. She had a healthy sister (mar-
ried with one healthy son) aged 34. Their mother suffered 
an anteroseptal myocardial infarction at the age of 46, as 
well as dyslipidaemia and diabetes mellitus, diagnosed 
at the time of myocardial infarction, and treated with in-
sulin as an initial treatment (Mixtard 30 Penfill® 38 units 
in the morning 18 units in the afternoon). At the time of 
her myocardial infarction she had a normal body weight 
(BMI 24 kg/m2). Two years later the mother was also found 
to have toxic multinodular goitre and was treated with 
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radioactive iodine. As her periods were regular during 
her reproductive years, she had never been investigated 
for potential hyperandrogenaemia or the presence of 
polycystic ovaries. 
On examination the patient had a normal body weight 
(57 kg, height 160 cm, BMI 22.27 kg/m2) and appeared 
strongly “muscular”, though she denied doing any 
body-building exercises or taking dietary/muscle-building 
supplements (Fig. 1A). There was a moderate hirsutism 
(15 points on the Ferrimann-Galwey scale) but no clitoro-
megaly. An overnight 1.0 mg dexamethasone suppression 
test was performed before her admission and revealed 
satisfactory suppression of cortisol release (0.65 µg/dL/18 
nmol/L), thus excluding hypercortisolaemia according 
to current guidelines [1]. Pelvic ultrasound examination 
revealed polycystic ovarian morphology.
Initial hormonal tests and lipids are presented in Table I.
Oral glucose tolerance test (OGTT) with insulin meas-
urements was performed and revealed striking insulin 
resistance, i.e. out of proportion to her normal BMI, with 
glucose excursions into a diabetic range (Table II). She had 
a high insulin resistance index, calculated according to the 
Belfiore method [2], as well as high HOMA, calculated 
according to the formula HOMA = [glucose (mmo/L)] 
× [insulin (µIU/mL)]/22.5 [3]. 
Further tests revealed normal 17-hydroxy-proges-
terone responses during 250-µg short-Synacthen test, 
thus excluding congenital adrenal hyperplasia (Table 
III). Given the diagnosis of diabetes mellitus and her 
young age she was screened for antibodies typical for 
type 1 diabetes (in case of coexistent LADA — latent 
autoimmune diabetes in adults). The above-mentioned 
autoimmune screen was negative (Table IV).
Late onset (non-classical) congenital adrenal hy-
perplasia is suspected when 17-hydroxy-progesterone 
response to 250 µg Synacthen exceeds 10 ng/mL 
(30 nmol/L) [4]. In view of the above findings a suspi-
cion of lipodystrophy was made, and she was referred 
Figure 1. Photographs depicting an anterior, side, and posterior view of a FPLD2-affected patient at the age of 31 years (A) and her 
affected mother at the age of 56 years (B) (reproduced with informed consent obtained from both patients)
Rycina 1. Fotografie przedstawiające pacjentki z FPLD2 od przodu, z boku i tyłu; pacjentka 31-letnia (A) i jej matka w wieku 56 lat 
(B) (zamieszczone po uzyskaniu świadomej zgody obu pacjentek)
552
Familial partial lipodystrophy and PCOS Krzysztof C. Lewandowski et al.
O
PI
S 
PR
ZY
PA
D
K
U
for genetic evaluation in the Department of Genetics, 
Polish Mother ’s Memorial Hospital — Research In-
stitute, Lodz, Poland. Based on direct DNA sequenc-
ing of the LMNA gene the patient was diagnosed 
with familial partial lipodystrophy (FPLD2, OMIM 
#151660) caused by lamin A/C gene R482Q mutation 
(LMNA — NM_005572.3) (Fig. 2). Molecular diagnostic 
testing was performed in the Department of Clinical 
and Laboratory Genetics, Medical University in Lodz, 
Poland. Once a diagnosis of partial lipodystrophy was 
established in our patient, her mother, with a history 
of early myocardial infarction and diabetes mellitus, 
was also investigated. On examination she was found 
to have a similar body habitus, suggestive for partial 
lipodystrophy (Fig. 1B). She was eventually found to 
harbour the same mutation in the lamin A/C gene, 
thus confirming the presence of familial partial lipod-
ystrophy. Family tree depicting both cases is presented 
in Figure 3.
In view of her marriage plans and possible future 
pregnancy slow release metformin therapy was started 
(Glucophage XR 750® up to 1500 mg/day and Dydro-
gesterone (Duphaston®) between the 16th and 25th day 
of menstrual cycle). A clinical review after about six 
months revealed her stable condition with an excellent 
glycaemic control with an HbA1c of 5.2%. No change in 
her medication was undertaken at this point.
Discussion
Polycystic ovary syndrome (PCOS) is one of the most 
common endocrinopathies affecting 4–8% of women in 
reproductive age [5]. PCOS is characterised by ovarian 
dysfunction (oligo- or anovulation), hyperandroge-
naemia and/or hyperandrogenism, and/or polycystic 
ovaries, where according to current diagnostic criteria 
[6] other causes of menstrual irregularities and hyperan-
drogenism have been ruled out. We describe the case of 
Table I. Initial hormonal and metabolic parameters of 
a 31-year-old patient with a history of oligomenorrhoea and 
hirsutism (BMI 22.27 kg/m2)
Tabela I. Wstępne parametry metaboliczne i hormonalne 
31-letniej pacjentki z wywiadem oligomenorrhoea 
i hirsutyzmu (BMI 22,27 kg/m2)
Parameter Concentration/Titre Reference range
HbA1c (%) 6.89 < 6
TSH [µIU/mL] 2.12 0.27–4.2
fT3 [pg/mL] 3.61 2.6–4.4
fT4 [ng/mL] 0.87 0.98–1.63
Anti-TPO antibodies [IU/mL] < 10 < 34
Anti-Thyroglobulin antibodies 
[IU/mL]
< 10 < 115
LH [IU/L] 3.88 2.4–12.6
FSH [IU/L] 2.54 3.5–12.5
Estradiol [pg/mL] 198 12.5–166
Testosterone [ng/mL] 0.47 0.084–0.481
Androstenedione [ng/mL] 4.1 0.3–3.3
DHEA-S [µg/dL] 395.7 98.8–340
Prolactin [ng/mL] 6.53 3.9–25.4
Triglycerides [mg/dL] 443 < 150
Total cholesterol [mg/dL] 198 < 200
HDL-cholesterol [mg/dL] 32 > 40
LDL-cholesterol [mg/dL] 98 < 100
Table II. Glucose and insulin during oral glucose tolerance 
test (75 g) in a 31-year-old patient investigated for 
oligomenorrhoea and hirsutism
Tabela II. Stężenie glukozy i insuliny w doustnym teście 
tolerancji glukozy (75 g) u 31-letniej pacjentki z wywiadem 
oligomenorrhoea i hirsutyzmu
0 minute 60 minutes 120 minutes
Glucose [mmol/L] 5.83 15.61 12.61
Insulin [mIU/mL]
[pmol/L]
19.59 
(117.5)
255.2
(1531)
231.0
(1386)
Conversion factor for insulin concentrations: 1 µU/mL = 6.00 pmol/L.
IRI — Insulin Resistance Index (gly-area): 1.81 (reference range: up to 1.25), 
HOMA 5.076 (where HOMA = [glucose (mmo/L)] × [insulin (µIU/mL)]/22.5) [3]
Table III. 250-µg Synacthen test for cortisol and 17-hydroxy-
progesterone secretion in a patient investigated for 
oligomenorrhoea and hirsutism
Tabela III. Test z 250 μg Synacthenu z oceną wydzielania 
kortyzolu oraz 17-hydroksy-progesteronu u badanej pacjentki 
z oligomenorrhoea i hirsutyzmem
0 minutes 30 minutes 60 minutes
Cortisol [µg/dL] 9.66 35.17 40.16
17-hydroxy-
progesterone
[ng/mL] 0.61 3.94 3.94
Table IV. Results of the screen for antibodies typical for type 
1 diabetes in a 31-year-old patient investigated for hirsutism 
and oligomenorrhoea
Tabela IV. Wyniki miana przeciwciał typowych dla cukrzycy 
typu 1 u 31-letniej pacjentki diagnozowanej z powodu 
hirsutyzmu i oligomenorrhoea
Diabetes-related antibodies Titre Reference range
IAA [IU/mL] 0.4 0–2.4
IA-2Ab [IU/mL] < 10.0 0–10
Anti-GAD [IU/mL] < 10 0–10
IAA — insulin autoantibodies, IA-2Ab — protein tyrosine phosphatase-like 
protein antibodies, anti-GAD — anti-glutamic acid decarboxylase antibodies
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a normal-weight 31-year-old woman with typical 
features of PCOS (clinical, hormonal, as well as a poly-
cystic ovarian morphology) accompanied, however, by 
profound insulin resistance and diabetes. Additionally, 
clinical examination revealed a “muscular” appearance 
with visible paucity of adipose tissue. In a standard situ-
ation patients who appear muscular typically have very 
good insulin sensitivity. In this case, however, the patient 
was found to be profoundly insulin resistant during 
OGTT, with peak insulin concentrations during OGTT 
exceeding 1500 pmol/L, which, according to Semple et 
al. [7], is suggestive of possible genetic syndromes associ-
ated with severe insulin resistance. Furthermore glucose 
levels at 120 minutes were already within diabetic range. 
Her mother had a similar body habitus, with early onset 
of cardiovascular complications (myocardial infarction at 
the age of 46) that coincided with a diagnosis of diabetes 
mellitus, treated with insulin since the time of diagnosis. 
It should be noted that her mother was originally con-
sidered to have type 1 diabetes because of relatively high 
glucose levels (about 300 mg/dL) in the setting of normal 
body mass index (24 kg/m2) and relatively high insulin 
requirement (50 units/per day with body weight of 
60 kg, i.e. 0.83 unit/kg). Final diagnosis was, however, 
only confirmed once partial lipodystrophy was diag-
nosed in her daughter. The phenotype with muscular 
hypertrophy and marked insulin resistance led us to 
screen for genes involved in familial partial lipodystro-
phy. The patient proved to be heterozygous for the mu-
tation in the LMNA gene. We recognised familial partial 
lipodystrophy of Dunnigan variety [8] (FPLD2, OMIM 
#151660), complicated by severe insulin resistance and 
diabetes with secondary PCOS. 
To the best of our knowledge this is the first case 
familial partial lipodystrophy described in Poland in 
the context of differential diagnosis of PCOS.
PCOS is thought to be a familial polygenic condition 
that is attributed to both genetic and environmental 
factors. There has been much debate about the aeti-
opathogenesis of PCOS in the past decade. Recently, 
several studies have indicated that a defect in insulin 
action may be the primary cause of PCOS. Thus, it 
should be kept in mind that Mendelian forms of in-
sulin resistance, for which the genetic basis is known, 
have been described. Mutations in the insulin receptor 
(INSR) gene may result in a broad range of phenotypes 
such as severe autosomal recessive Donohue syndrome 
(Leprechaunism), which combines somatic anomalies 
and dysmorphic features with hyperinsulinaemia, hy-
pertrichosis, acanthosis nigricans, and hypoglycaemia 
[9]. INSR mutations may also result in diabetes, insulin 
resistance, and acanthosis nigricans without other as-
sociated anomalies. Another group of disorders to be 
considered include lipodystrophies, which consist of 
a loss of body fat and insulin resistance. At least 11 genes 
with mutations have been reported so far. Two of the 
more common disorders include congenital generalised 
lipodystrophy, an autosomal recessive disorder with at 
least four genes (AGPAT2, BSCL2, CAV1, PTRF) identi-
fied, and familial partial lipodystrophy, an autosomal 
dominant disorder where at least four genes (LMNA, 
PPARG, AKT3, PLIN1) have been identified [10].
Familial partial lipodystrophy of Dunnigan variety 
(FPLD) is a rare autosomal dominant disorder, first 
described by Dunnigan et al. in 1974 [8], with over 
300 subsequent patients being reported. It is caused by 
heterozygous mutations in the lamin A/C (LMNA) gene 
with a hot spot in C-terminal Ig-like domain. About 
85% of FPLD2 patients present mutation at LMNA 
codon 482, substituting a basic amino acid (arginine) 
for a neutral one (glutamine, tryptophan). Knowledge 
on molecular mechanisms of LMNA-linked lipodys-
Figure 2. Fluorescent peak trace chromatogram showing LMNA 
sequence with a base substitution from G to A in one allele. 
Mutation results in arginine to glutamine substitution (R482Q) 
at the protein level
Rycina 2. Chromatogram fluorescencyjny pokazujący sekwencję 
LMNA z zamianą pary zasad (G do A) w jednym allelu. Mutacja 
powoduje zamianę argininy na glutaminę (R482Q) w strukturze 
białka Figure 3. Family tree depicting both a 31-year-old patient and 
her mother. The described FPLD2 affected patient marked by an 
arrow (→)
Rycina 3. Drzewo genealogiczne 31-letniej pacjentki i jej matki. 
Opisana pacjentka z FPLD2 zaznaczona strzałką (→)
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trophy remains scarce. Lamins encoded by the LMNA 
gene are intermediate filaments and are located at the 
filamentous network underlying the inner nuclear 
membrane. They interact with a variety of proteins in 
the nucleus and are important for nucleus assembly, 
structure, shape, and stability.
Patients with FPLD2 have normal fat distribution 
during childhood, but, following puberty, typically 
develop progressive loss of subcutaneous fat in the 
arms and legs with variable loss of fat in the body cor-
pus, and often excess fat deposition in the face, neck, 
and intra-abdominal regions. Interestingly, prominent 
lipoatrophy is accompanied by an extensive muscu-
lature in patients with FPLD2. The phenomenon was 
recently explained with the discovery of interplay of 
FXRP1 and LMNA proteins in preadipocytes. R482 
substitution abrogates lamin A interaction with FXRP1 
protein leading to delocalisation and accumulation 
of the latter. The process, in turn, elicits switching an 
adipogenic differentiation into a myogenic program 
[11]. Other notable features include acanthosis nigri-
cans and hepatomegaly (not present in our patient). 
Metabolic abnormalities related to insulin resistance 
such as diabetes mellitus, hypertriglyceridaemia, and 
hepatic steatosis are commonly noted. Metabolic ab-
normalities associated with FPLD typically manifest in 
early adulthood. Hypertriglyceridaemia is a common 
finding in FPLD and can be severe, potentially leading to 
acute pancreatitis. Finally, some patients with FPLD may 
develop myopathy, cardiomyopathy, and/or conduction 
system abnormalities.
A significant proportion of patients with FPLD 
develop hirsutism, menstrual abnormalities, polycys-
tic ovaries, and other gynaecological complications 
necessitating, in some cases, early oophorectomy or 
hysterectomy [12]. These signs of androgen excess 
probably result from both the decrease in sex-hormone 
binding globulin (SHBG) production from the liver 
caused by hyperinsulinaemia, and the direct effect 
of insulin on theca cells leading to androgen produc-
tion. Interestingly, there is evidence that insulin per se 
stimulates ovarian growth, even in the setting of low, 
e.g. prepubertal, gonadotropin concentrations [13], 
while treatment with leptin therapy improves insulin 
sensitivity leading to a fall in androgen concentrations 
and an increase in SHBG [14]. There is also evidence 
that thiazolidinediones are superior to metformin in 
the treatment of FPLD [15]. However, in view of the 
procreative plans of our patient, her good glycaemic 
control on a diet and metformin, as well as a lack of any 
reimbursement of the costs of thiazolidinediones in the 
Polish health insurance system, we decided to continue 
treatment with metformin with plans to instigate in-
sulin treatment, once her final plans for pregnancy are 
established. However, we keep in mind the possibility 
of pioglitazone treatment after possible pregnancy and 
breastfeeding in case of significant deterioration of her 
glycaemic control.
In summary, although the association of PCOS with 
obesity and insulin resistance is well known, not all 
women with PCOS are clinically obese. The reported 
case underlines the importance of physical examina-
tion, which can suggest important hints to diagnoses 
that extend beyond the standard range of conditions 
associated with oligomenorrhoea and/or hirsutism/ 
/hyperandrogenaemia. Recognition of lipodystrophy 
is, however, very important for the later diagnosis 
of more serious metabolic abnormalities in patients 
and their families. Hence, the awareness of a possibil-
ity of familial partial lipodystrophy is important for 
both endocrinologists and gynaecologists, as well as 
for physicians involved in the treatment of diabetes 
mellitus. Our case is thus an important reminder that 
the assessment of insulin sensitivity and adipose tis-
sue topography is a key part of the initial evaluation 
of patients with PCOS. It is important to consider the 
diagnosis of FPLD in lean, muscular women who have 
polycystic ovarian syndrome.
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